UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2024

OrthoPediatrics Corp. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-38242

(Commission File Number)

26-1761833

(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana (Address of principal executive offices)

46582 (Zip Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00025 par value per share	KIDS	Nasdaq Global Market

Registrant's telephone number, including area code: (574) 268-6379 Not Applicable (Former name or former address, if changed since last report)

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Check

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act 🗆

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.2 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.2, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits

Exhibits	
Exhibit No.	Description
<u>99.1</u>	Orthopediatrics Corp. Investor Presentation dated March 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OrthoPediatrics Corp.

Date: March 11, 2024

By:

/s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary

- 2 -





Disclaimer


Forward-Looking Statements All statements of historical facts, contained in this quarterly report, including datements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-booking statements. In some cases, you can identify forward-booking statements by terms such as "may," "will," "should," "papedt," "roukd," "intend," Target," "projedt," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. We have based these forward-booking statements speek only as of the date of this report. Forward-booking statements, such as do the date of this report. Forward-booking statements should," many such as "may," "will," "should," "south gatements involve from and uninnown risks, uncertainties and dher factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytal virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-booking statements. and there, and there, such as a three, and thore also can be assed in performance for a billey to achieve or sustain profitability in the future; curvability to raise additional capital to fund our existing commercial perations, develop and conmercialize adex our preations, our ability to achieve and sustain profitability to complex to do so we may be unable to complete effectively; our ability to achieve from the information and oversight bath in the Unted States and abroad; our ability to achieve and our envork of thid-party independent sales agencies and expand-our ability to perfet our infeled able abroad; our ability to achieve and sustain formation and expand our network of thid-party independent sales agencies and expand-our advorked able and sustain to forward-booking statements. A and you are enourage


Use of Non-GAAP Financial Measures
This press release includes certain non-GAP financial measures such as adjusted diuted bos (earnings) per share and Adjusted EBITDA, which dffer from financial measures calculated in accordance with U.S. generally
accepted accounting principles ("GAP"). Adjusted bos (earnings) per share in this press release represents diuted bos (earnings) per share on a GAP basis, plus the accreted interest attributable to acquisition
instalment payables, the fair value adjustment of contingent consideration, trademark impairment, acquisition related costs, non-recurring Pega conversion fees, and minimum purchase commitment costs. The fair value
expenses, as well as the GAP measures, asskits our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net to see, blue fit, depreciation and anotization, trademark impairment, dockbased compensation express, fair value adjustment of contingent consideration, associated with our expense, private adjustment of contingent consideration, associated and anotization, trademark impairment, dockbased compensation express, fair value adjustment of contingent consideration, acquisition
related costs, nonrecurring Pega conversion fees, and the cost of minimum purchase commitments. The Company believes the non-GAP diluted to set (barefit), depreciation and anotization, trademark impairment, dockbased compensation express, fair value adjustment of contingent consideration, acquisition
related costs, nonrecurring Pega conversion fees, and the cost of minimum purchase commitments. Measument use, to a superior to neasure of the cost paining
purposes, including financial projections. The Company believes these measures are useful to investors as an attemative to, or superior to, net income or loss as a measure of the cost partition and oncica to income consistent and anotication, related and to considered as a alternative to, or superior to, net income or loss as a measure of the cost period


2024 // Investor Presentation





























Acquired Innovative Technologies -

State-of-the-Art Products - - That Better Each Patient's Life

Boston Orthotics & Prosthetics


- Pioneered the original patient-specific, custom
 Boston Scoliosis Brace
- Currently has 5 disease state focuses with 17
 different product offerings
- Custom manufacturing and fabrication center based outside of Boston, MA
- Newly established **headquarters** for the OrthoPediatrics Specialty Bracing (OPSB) division
- Owns and operates 26 pediatric / adolescent focused O&P clinics (w/CPOs) in 10 states, mainly New England area


Terms:

- Closed January 5, 2024
- \$22M Cash











MD Orthopaedics

- Develops, manufactures and sells the patented Mitchell Ponseti Ankle-Foot Orthosis (AFO) to treat clubfoot
- Dr. Ignacio Ponseti developed the gold standard for treating clubfoot which has >90% success rate
- Casting is used from 0-3mos then bracing from 3mos-4 years. Requires multiple sizes as child grows creating repeat revenue.
- Products sold in 90 countries including e-commerce
 platform direct to consumers
- Approximately 80% of a pediatric surgeon's treatment time is non-surgical
- Creates a profitable platform business for OP to develop and manufacture best-in-class specialty bracing with speed to market (class 1 device) as well as no consignment inventory required to grow the business

Terms:

- Closed April 1, 2022
- \$8.2M cash, \$8.9M shares, \$2.5M RSA

2024 // Investor Presentation

Acquired Innovative Technologies Image: Acquired Innovati

PrthOPediatrics 18

Acquired Innovative Technologies -

Pega Medical

- Developed the Fassier-Duval Telescopic Intramedullary Nail System (FD Nail)
- FD Nail is cutting-edge implant designed to treat bone deformities in children with Osteogenesis Imperfecta without disrupting their normal growth
- Pega offers 7 products in total, 6 of which focus on limb deformity correction, and 1 trauma
- Products sold in 70 countries
- Approximately 35,000 children suffer from Osteogenesis Imperfecta in the U.S.

2024 // Investor Presentation

Terms:

- Closed July 5, 2022
- \$31M cash, \$2M stock



Pega Medical

Fassier-Duval Teles

Telescopic IM System[™] The nail that grow with your patient!





Orthex

- Disruptive software complements ex-fix frame
- Expands addressable market
- Serve 85% of procedures, up from 65%
 Significantly simplifies surgical planning and alignment
- Enables participation in most complex surgeries

ApiFix

- Disruptive non-fusion technologyViable alternative to failed bracing &
- spinal fusion

2024 // Investor Presentation

- Posterior, minimally invasive approach
- Motion preserving capabilities
- Granted FDA HDE approval







Acquired Innovative Technologies

- Acquired software-based and non-fusion
 - technologies
- Significant sales synergies with legacy portfolio
- Expands critical KOL network
- Provides surgeons broadest product portfolio




PrthOPediatrice 20 -




















(\$ in Millions)

Income Statement Summary

4Q 2023

\$37.6

21%

\$26.7

71%

\$34.8

(\$8.1)

(\$6.7)

(\$0.29)

4Q 2022

\$31.0

25%

\$21.2

69%

\$29.5

(\$8.3)

(\$7.8)

(\$0.35)

	FY 2021	FY2022	FY2023
Revenue	\$98.0	\$122.3	\$148.7
Growth %	38%	25%	22%
Gross profit	\$73.4	\$90.7	\$111.3
Margin %	75%	74%	75%
Operating expenses	\$91.4	\$116.1	\$138.0
Operating loss	(\$18.0)	(\$25.4)	(\$26.8)
Net (loss) income	(\$16.2)	\$1.3	(\$21.0)
EPS diluted	(\$0.84)	\$0.06	(\$0.92)

2024 // Investor Presentation

OrthOPediatrice 29 -

(\$ in Millions)

	Three Months Ended December 31,		
Product Sales by geography	2022	2023	
U.S.	\$22.7	\$28.3	
International	8.3	9.3	
Total Revenue	\$31.0	\$37.6	
		nths Ended 1ber 31,	

Product Sales by category	2022	2023
Trauma and deformity	\$22.1	\$27.1
Scoliosis	8.0	9.6
Sports medicine/other	0.9	0.9
Total Revenue	\$31.0	\$37.6

Revenue Bv	Geography and	Product Category
	obogiapity and	

		nths Ended ber 31,
Product Sales by geography	2022	2023
U.S.	\$92.4	\$111.0
International	29.9	37.7
Total Revenue	\$122.3	\$148.7
	Twelve Months Ende December 31,	
	Decem	ber 31,
Product Sales by category	Decem 2022	ber 31, 2023
Product Sales by category Trauma and deformity		
	2022	2023
Trauma and deformity	2022 \$85.1	2023 \$106.8

2024 // Investor Presentation

OrthOPediatrice 30

(\$ in Millions)

Adjusted EBITDA Reconciliation

	Three Months Ended December 31,			fonths Ended mber 31,	
	2022	2023	2022	2023	
Net (loss) income	(\$7.8)	(\$6.7)	\$1.3	(\$21.0)	
Interest (income) expense, net	(0.1)	(0.3)	2.4	(0.2)	
Other (income) expense	0.1	(0.9)	1.8	(2.3)	
Provision for income taxes (benefit)	0.0	(0.2)	(4.9)	(0.3)	
Depreciation and amortization	3.8	5.5	13.4	17.4	
Stock-based compensation	1.6	2.5	6.7	10.5	
Trademark impairment	-	-	3.6	1.0	
Fair value adjustment of contingent consideration	(0.5)	0.0	(25.9)	(3.0)	
Acquisition related costs	-	0.5	0.8	0.7	
Nonrecurring Pega conversion fees	-	-	-	0.3	
Minimum purchase commitment cost	0.7	0.9	1.1	2.0	
Adjusted EBITDA	(\$2.2)	\$1.3	\$0.2	\$5.0	

2024 // Investor Presentation

OrthOPediatrice 31 -

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2022	2023	2022	2023
Loss (income) per share, diluted (GAAP)	(\$0.35)	(\$0.29)	\$0.06	(\$0.92)
Accretion of interest attributable to acquisition installment payable	0.02	0.01	0.11	0.05
Fair value adjustment of contingent consideration	(0.02)	-	(1.25)	(0.13)
Trademark impairment	-	-	0.17	0.04
Acquisition related costs	-	0.02	0.04	0.03
Nonrecurring Pega conversion fees	-	-	-	0.01
Minimum purchase commitment cost	0.03	0.04	0.05	0.09
Adjusted loss per share, diluted (non-GAAP)	(\$0.32)	(\$0.22)	(\$0.82)	(\$0.83)

(\$ in Millions) As of December 31, 2023

Assets	
Cash, cash equivalents & short-term investments	\$82.3
Account receivable	34.6
Inventory (net)	105.8
Other current assets	3.8
Total Current Assets	226.5
PP&E (net)	41.0
Intangibles and goodwill	171.2
Total Assets	\$438.7

Liabilities	
Accounts payable	\$12.6
Debt	10.0
Accrued comp. & other liab.	25.3
Acquisition pay. & cont. consideration	13.7
Paid-in capital	580.3
Accumulated deficit (net)	(197.7)
Accumulated other comprehensive loss	(5.5)
Total Liabilities / Equity	\$438.7

2024 // Investor Presentation

OrthOPediatrics 33

(\$ in Millions	;)		Full Year 2024 Guidance —
	2024 Guidance		
		FY2024	
	Revenue	\$197.0 to \$200.0	
	Adjusted EBITDA	\$8.0 to \$9.0	
	Assumptions		
		FY2024	
	2024 Total Revenue Growth %	32% to 34%	
	Set Deployment	<\$20.0	
	or Presentation		OrthOPediatricz 34 -



